Lyell Immunopharma, Inc.
LYEL
$11.02
-$0.79-6.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.20M | -191.94M | -44.58M | -45.81M | -60.67M |
| Total Depreciation and Amortization | 3.44M | 5.03M | 4.68M | 4.90M | 5.02M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.57M | 139.63M | 3.82M | 3.77M | 16.86M |
| Change in Net Operating Assets | -9.55M | 34.00K | 1.04M | -954.00K | -3.24M |
| Cash from Operations | -54.74M | -47.24M | -35.04M | -38.09M | -42.02M |
| Capital Expenditure | -246.00K | -44.00K | -59.00K | -331.00K | -30.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -31.35M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.71M | 84.90M | 1.98M | 45.34M | 22.02M |
| Cash from Investing | 69.47M | 53.51M | 1.92M | 45.01M | 21.99M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 437.00K | 0.00 | 862.00K | 103.00K |
| Repurchase of Common Stock | -- | 0.00 | 0.00 | 0.00 | -76.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.00K | -- | -- | -- | -- |
| Cash from Financing | 1.00K | 437.00K | 0.00 | 862.00K | 27.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.73M | 6.70M | -33.12M | 7.78M | -20.00M |